A previous study showed that the PI3K/Akt/mTOR pathway was constitutively active in EBV-positive B lymphomas from patients with PTLD, and that SRL combined with PI3K-δ inhibitor synergistically suppressed the proliferation of EBV-positive B lymphoma cells (97). Here, MTOR is linked to post-transplant lymphoproliferative disease.